Compare Hims and Hers Health Inc (HIMS) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs CarMax, Inc — how do they compare? Hims and Hers Health Inc trades at $29.4 (market cap $6.55B), while CarMax, Inc trades at $52.88 (market cap $7.64B). The key difference: CarMax, Inc is the larger of the two by market cap, and CarMax, Inc is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and CarMax, Inc for 49 Days on average.
| HIMS | KMX | |
|---|---|---|
Market Cap | $6.55B | $7.64B |
Volume | 14,842,814 | 3,610,116 |
Sector | Health | Consumer Cyclical |
52-Week High | $62.76 | $64.22 |
52-Week Low | $14.52 | $30.88 |
Typical Hold Time | 21 Days | 49 Days |
Enterprise Value | $7.25B | $25.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
CarMax (KMX) trades at $53.28, down 3.64% amid bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with strong revenue growth (Q2 2026 revenue up 19.5% to $7.9B) but thin net margins (1.06%). Analyst consensus leans cautious with 62% hold ratings, though price targets suggest 10.5% upside to $58.89. Recent leadership appointments and strategic updates signal management's focus on growth execution.
Outlook hinges on CarMax's ability to sustain unit sales momentum while improving profitability. The stock offers value appeal (P/S 0.28) but faces execution risks from high debt ($18.1B long-term) and competitive pressures. Near-term catalysts include November's strategic webcast and Q3 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
